CA2146668A1 - Activite tumoricide d'ansamycines benzoquinonoides contre le cancer de la prostate et les tumeurs malignes primitives du systeme nerveux - Google Patents

Activite tumoricide d'ansamycines benzoquinonoides contre le cancer de la prostate et les tumeurs malignes primitives du systeme nerveux

Info

Publication number
CA2146668A1
CA2146668A1 CA002146668A CA2146668A CA2146668A1 CA 2146668 A1 CA2146668 A1 CA 2146668A1 CA 002146668 A CA002146668 A CA 002146668A CA 2146668 A CA2146668 A CA 2146668A CA 2146668 A1 CA2146668 A1 CA 2146668A1
Authority
CA
Canada
Prior art keywords
group
composition
derivatives
ansamycin
geldanamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002146668A
Other languages
English (en)
Inventor
Luke Whitesell
Leonard Neckers
Jane Trepel
Charles Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2146668A1 publication Critical patent/CA2146668A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002146668A 1992-10-14 1993-10-14 Activite tumoricide d'ansamycines benzoquinonoides contre le cancer de la prostate et les tumeurs malignes primitives du systeme nerveux Abandoned CA2146668A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96125092A 1992-10-14 1992-10-14
US07/961,250 1992-10-14
PCT/US1993/009858 WO1994008578A2 (fr) 1992-10-14 1993-10-14 Activite tumoricide des ansamycines benzoquinonoides contre le cancer de la prostate et les malignites neurales primitives

Publications (1)

Publication Number Publication Date
CA2146668A1 true CA2146668A1 (fr) 1994-04-28

Family

ID=25504242

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002146668A Abandoned CA2146668A1 (fr) 1992-10-14 1993-10-14 Activite tumoricide d'ansamycines benzoquinonoides contre le cancer de la prostate et les tumeurs malignes primitives du systeme nerveux

Country Status (5)

Country Link
EP (1) EP0664702A1 (fr)
JP (1) JPH08502488A (fr)
AU (1) AU5360694A (fr)
CA (1) CA2146668A1 (fr)
WO (1) WO1994008578A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1413885A3 (fr) * 1997-04-02 2004-08-11 Takeda Chemical Industries, Ltd. Utilisation et méthode de criblage d'un activeur d'un produit génétique aberrant
WO1999051223A1 (fr) * 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Ansamycines benzoquinoides pour le traitement d'une crise ou d'un arret cardiaque
AU2986800A (en) * 1999-02-08 2000-08-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of inhibiting the hgf-met-upa-plasmin network
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US7241754B2 (en) 2003-06-13 2007-07-10 Kosan Biosciences, Inc. 2-Desmethyl ansamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
EP1682514A4 (fr) 2003-11-12 2008-07-16 Kosan Biosciences Inc Composes 11-o-methylgeldanamycine
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
WO2005095347A1 (fr) * 2004-03-26 2005-10-13 Van Andel Research Institute Geldanamycine et ses derives pouvant inhiber une proliferation cancereuse et identifier de nouvelles cibles
US7259156B2 (en) 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
WO2006098761A2 (fr) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Inhibiteurs hsp90, procedes de realisation et d'utilisation correspondants
EP2361903A1 (fr) * 2005-06-29 2011-08-31 Kyowa Hakko Kirin Co., Ltd. Dérivé benzénoïde de l'ansamycine
GB0606554D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
GB0606542D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
GB0609117D0 (en) * 2006-05-09 2006-06-21 Biotica Tech Ltd Novel compounds
DK2091919T3 (da) 2006-11-15 2011-12-05 Abraxis Bioscience Llc Derivater af 18-amino-substituerede analoge af geldamycinhydroquinon med cytotoksisk aktivitet til behandling af cancer
US8551964B2 (en) 2007-08-23 2013-10-08 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
CA2699794C (fr) 2007-09-10 2016-07-19 University Of Massachusetts Agents antitumoraux ciblant les mitochondries
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111B (en) * 1981-09-17 1985-11-06 Takeda Chemical Industries Ltd Macbecin derivatives and their production

Also Published As

Publication number Publication date
EP0664702A1 (fr) 1995-08-02
AU5360694A (en) 1994-05-09
WO1994008578A3 (fr) 1994-06-23
WO1994008578A2 (fr) 1994-04-28
JPH08502488A (ja) 1996-03-19

Similar Documents

Publication Publication Date Title
CA2146668A1 (fr) Activite tumoricide d'ansamycines benzoquinonoides contre le cancer de la prostate et les tumeurs malignes primitives du systeme nerveux
EP2332542B1 (fr) Utilisation de taurolidine ou de taurultame pour la fabrication d'un medicament pour traiter des tumeurs
Wahl et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
Bino et al. Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells
DE69412251T2 (de) Aromatische nitro verbindungen und deren metabolite verwendbar als anti-virus-und anti-tumormittel
Pantazis et al. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins
Sebolt et al. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro
CA2458459A1 (fr) Combinaisons anti-cancer
US6214821B1 (en) Methods and composition for the inhibition of cancer cells
AU2002324143A1 (en) Combinations of dxmaa and other anti-cancer agents
US4628047A (en) Agent for enhancing antitumor activity of antitumor agent
AU2005265155A1 (en) Cancer chemotherapy
Osmak et al. Ascorbic acid and 6-deoxy-6-chloro-ascorbic acid: potential anticancer drugs
US20070149554A1 (en) Cancer chemotherapy
JP2007523191A (ja) 血液腫瘍の治療のためのβ−ラパコンの使用
AU4338493A (en) Treatment of cancers
US5994328A (en) Hypoestoxides, derivatives and agonists thereof for use as anticancer agents
US6812255B2 (en) Use of aloe-emodin in the treatment of neuroectodermal tumors
Garg et al. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma
Pollack et al. The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors
AU2001267494A1 (en) Use of aloe-emodin in the treatment of neuroectodermal tumors
JP2007523190A (ja) 肺癌の治療のためのβ−ラパコンの使用
Braakhuis et al. Preclinical antitumor activity of 5-aza-2′-deoxycytidine agains human head and neck cancer xenografts
EP1313459B1 (fr) Dianthraquinones polycycliques utilisees comme agents anticancereux et anti-angiogeniques
CN111773388A (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用

Legal Events

Date Code Title Description
FZDE Dead